Overview
IgG4-related ophthalmic disease (also called IgG4-related orbital disease or IgG4-related eye disease) is a condition where the immune system causes chronic inflammation in and around the eyes. It is part of a broader group of conditions known as IgG4-related disease (IgG4-RD), which can affect many organs in the body. In this form, the disease specifically targets the tissues around the eye, including the tear glands (lacrimal glands), the eye muscles, the fat and connective tissue within the eye socket (orbit), and sometimes the eyelids. Patients typically notice painless swelling around one or both eyes, which may cause the eyes to appear puffy or bulging. The tear glands are commonly enlarged, which can lead to dry eyes or excessive tearing. Some people experience double vision if the eye muscles become involved, and in more severe cases, vision can be affected if swollen tissue presses on the optic nerve. The swelling tends to develop slowly over weeks to months. IgG4-related ophthalmic disease is not a cancer, but it can mimic tumors on imaging scans, which is why a biopsy is usually needed for diagnosis. The hallmark finding under the microscope is a dense infiltration of IgG4-positive plasma cells along with a characteristic pattern of fibrosis (scarring). Blood tests often show elevated levels of IgG4 antibodies, though not always. Treatment typically involves corticosteroids (such as prednisone), which usually produce a good initial response. For patients who relapse or cannot tolerate steroids, other immunosuppressive medications or the targeted drug rituximab may be used. Early diagnosis and treatment are important to prevent permanent scarring and damage to the eye structures.
Key symptoms:
Painless swelling around one or both eyesPuffy or swollen eyelidsBulging of the eye (proptosis)Enlarged tear glandsDry eyesExcessive tearingDouble visionBlurred visionFeeling of pressure behind the eyeRestricted eye movementRedness of the eye or eyelidGradual vision loss if the optic nerve is compressedFirm, painless mass in the eye socket area
Clinical phenotype terms (42)— hover any for plain English
Sporadic
Usually appears on its own, not inherited from a parent
Adult
Begins in adulthood (age 18 or older)
Treatments
No FDA-approved treatments are currently listed for IgG4-related ophthalmic disease.
View clinical trials →Clinical Trials
View all trials with filters →No actively recruiting trials found for IgG4-related ophthalmic disease at this time.
New trials open frequently. Follow this disease to get notified.
Rare Disease Specialist
Treatment Centers
8 centersNational Institutes of Health Clinical Center
📍 Bethesda, Maryland
👤 Payal P Khincha, M.D.
👤 Christopher Grunseich, M.D.
Stanford Medicine Rare Disease Center ↗
Stanford Medicine
📍 Stanford, CA
🏥 NORDMayo Clinic Center for Individualized Medicine ↗
Mayo Clinic
📍 Rochester, MN
👤 Mayo Clinic Center for Individualized Medicine
🔬 UDNUCLA UDN Clinical Site ↗
UCLA Health
📍 Los Angeles, CA
🔬 UDNBaylor College of Medicine UDN Clinical Site ↗
Baylor College of Medicine
📍 Houston, TX
🔬 UDNHarvard/MGH UDN Clinical Site ↗
Massachusetts General Hospital
📍 Boston, MA
🔬 UDNNIH Clinical Center Undiagnosed Diseases Program ↗
National Institutes of Health
📍 Bethesda, MD
🏥 NORDBaylor College of Medicine Rare Disease Center ↗
Baylor College of Medicine
📍 Houston, TX
Travel Grants
No travel grants are currently matched to IgG4-related ophthalmic disease.
Community
No community posts yet. Be the first to share your experience with IgG4-related ophthalmic disease.
Start the conversation →Latest news about IgG4-related ophthalmic disease
Disease timeline:
New trial: National Ophthalmic Genotyping and Phenotyping Network (eyeGENE (Registered Trademark)), Stage 3 - E
Phase NA trial recruiting.
Caregiver Resources
NORD Caregiver Resources
Support, advocacy, and financial assistance for caregivers of rare disease patients.
Mental Health Support
Rare disease caregiving can be isolating. Connect with counseling and peer support.
Family & Caregiver Grants
Financial assistance programs specifically for caregivers of rare disease patients.
Social Security Disability
Learn how rare disease patients may qualify for SSDI/SSI benefits.
Questions for your doctor
Bring these to your next appointment
- Q1.How certain is the diagnosis, and do I need a biopsy to confirm it?,Are any other organs affected by IgG4-related disease, and how will you check for that?,What treatment do you recommend first, and what are the side effects I should watch for?,How long will I need to take steroids, and what is the plan for tapering them?,What are the chances my disease will come back after treatment, and how will we monitor for relapse?,Is rituximab an option for me if steroids alone are not enough?,Could this disease permanently affect my vision, and what can we do to prevent that?
Common questions about IgG4-related ophthalmic disease
What is IgG4-related ophthalmic disease?
IgG4-related ophthalmic disease (also called IgG4-related orbital disease or IgG4-related eye disease) is a condition where the immune system causes chronic inflammation in and around the eyes. It is part of a broader group of conditions known as IgG4-related disease (IgG4-RD), which can affect many organs in the body. In this form, the disease specifically targets the tissues around the eye, including the tear glands (lacrimal glands), the eye muscles, the fat and connective tissue within the eye socket (orbit), and sometimes the eyelids. Patients typically notice painless swelling around on
How is IgG4-related ophthalmic disease inherited?
IgG4-related ophthalmic disease follows a sporadic inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.
At what age does IgG4-related ophthalmic disease typically begin?
Typical onset of IgG4-related ophthalmic disease is adult. Age of onset can vary across affected individuals.
Which specialists treat IgG4-related ophthalmic disease?
20 specialists and care centers treating IgG4-related ophthalmic disease are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.